Firms

V-Bio Ventures

V-Bio Ventures

Ghent, Belgium

v-bio.ventureskbopub.economie.fgov.befsma.be

V-Bio Ventures is a Ghent-based independent life-sciences venture-capital platform founded in2015 by Christina Takke and Willem Broekaert. It co-creates and finances early- and mid-stage companies developing therapeutics and differentiated biomedical technologies, with a preferred relationship to the separate Belgian research institute VIB. Its historical investment strategy also includes agricultural biotechnology. Current scientific investment expertise includes molecular biology, translational research, targeted protein degradation and AI-enabled drug discovery; its portfolio’s computational and neurological research links do not establish approved clinical benefit or that every investment is an AI company. The current website lists seven investment/finance professionals and adviser Tom Schwarz, with former adviser Johan Cardoen explicitly memorialised after his December17,2025 death. The Belgian operating/advisory company V-Bio Ventures BV is enterprise0758.544.057, formedNovember18,2020, distinct from the platform’s2015 origin and its registered managers V-Bio Management1 BV(0641.986.877) and V-Bio Management2 BV(0758.543.760). Actual fund vehicles V-Bio Fund1 NV(0642.766.540) and Fund2 NV(0759.685.291) are separately documented. Own primary releases confirm Fund1’s finalEUR76million close announcedDecember1,2016 and Fund2’s finalEUR110million close announcedMarch31,2022. The earlier63million and78million first closes belong to those same vehicles and are not additional funds or extra fundraising totals. The current website’s186million aggregate across two funds is managed-capital reporting, not a third fund close or company investment ticket. Explicit portfolio listings distinguish active and divested relationships, including neuroscience drug discovery and neurological-disease therapeutics; exits with maximum milestone values are not asserted as cash received. Actual issuer releases identify the institutional brand as a buyer, while an individual legal fund allocation is recorded only when published. VIB’s research functions, regulatory-grant programmes and a partner’s board service are not substituted for V-Bio’s separate corporate investment.

Founded
2015
Type
Venture capital

Funds2

  • V-Bio Fund2 NV€110M

    Actualfinal110MEURclosedfundannouncedMarch31,2022, legalNV0759685291 begunDecember11,2020. Manager2BV0758543760 corporatefunddirector. First78MFebruary4,2021/interim96MJanuary2022samefund; excludedasadditionalfunds or cashsum. EIFsupport30Mnotwholefundsize or automaticcompanyticket.

  • V-Bio Fund1 NV€76M

    Actualfinal76MEURclosedfundannouncedDecember1,2016, legalNV0642766540 begunNovember9,2015. Manager1BV0641986877 corporatefunddirector. First63McloseNovember2015samevehicle, notextra63Mfund. Registeredsharecapital/NAVnotadditionalclosingcash.

Team

Operations and support

Christina TakkeChristina TakkePermanent Representative, Fund2 corporate director Management2 · Director, V-Bio Ventures BV · Director, V-Bio Management2 BV · Permanent Representative, Fund1 corporate director Management1 · Director, V-Bio Management1 BV · Co-Founder and Managing Partner
Katja RosenkranzKatja RosenkranzPartner
Martin SolleveldMartin SolleveldFinance Manager
Mathias FalcenbergMathias FalcenbergVenture Partner
Shelley MargetsonShelley MargetsonDirector, V-Bio Ventures BV · Director, V-Bio Management2 BV · Managing Partner
Tom SchwarzTom SchwarzStrategic Advisory Board Member
Ward CapoenWard CapoenPartner
Willem BroekaertWillem BroekaertDirector, V-Bio Ventures BV · Director, V-Bio Management2 BV · Director, V-Bio Management1 BV · Co-Founder and Managing Partner

Co-investing

Investments

$73M2021-07-09Muna TherapeuticsNovo Holdings, Droia Ventures, Sanofi Ventures, V-Bio Ventures, VIB (Flanders Institute for Biotechnology)
$—2025-03-24Augustine TherapeuticsNovo Holdings, Jeito Capital, AdBio Partners, PMV (Participatiemaatschappij Vlaanderen), Gemma Frisius Fund, Asabys Partners, Newton Biocapital, V-Bio Ventures, Eli Lilly and Company, CMT Research Foundation, VIB (Flanders Institute for Biotechnology)
€17M2024-06-26Augustine TherapeuticsAsabys Partners, AdBio Partners, PMV (Participatiemaatschappij Vlaanderen), Gemma Frisius Fund, V-Bio Ventures, Eli Lilly and Company, CMT Research Foundation, VIB (Flanders Institute for Biotechnology)
€23M2022-10-04Sibylla BiotechV-Bio Ventures, Claris Ventures, Indaco Venture Partners SGR, Seroba Life Sciences, Vi Partners, 3B Future Health Fund, CDP Venture Capital SGR, Vertis SGR
€4M2019-12-16Augustine TherapeuticsAdBio Partners, PMV (Participatiemaatschappij Vlaanderen), Gemma Frisius Fund, V-Bio Ventures, VIB (Flanders Institute for Biotechnology)